References
- Shams PN, Plant GT.Optic neuritis: a review. Int MS J. 2009;16(3):82–89.
- Pau D, Al Zubidi N, Yalamanchili S, Plant GT, Lee AG. Optic Neuritis Eye 2011, 25(7), 833–42.
- Meltzer E, Prasad S. Updates and controversies in the management of acute optic neuritis. Asia Pac J Ophthalmol (Phila). 2018 Jul-Aug;7(4):251–56.
- Abou Zeid N, Bhatti MT.Acute inflammatory demyelinating optic neuritis: evidence-based visual and neurological considerations. Neurologist. 2008;14(4):207–23. doi:https://doi.org/10.1097/NRL.0b013e31816f27fe.
- Beck RW, Gal RL.Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol. 2008;126(7):994–95. doi:https://doi.org/10.1001/archopht.126.7.994.
- Michael Brodsky, Sarkis Nazarian, Silvia Orengo-Nania, George J. Hutton, Edward G. Buckley, E. Wayne Massey, M. Tariq Bhatti, Melvin Greer, James Goodwin, Michael Wall, Peter J. Savino, Thomas Leist, Neil R. Miller, David Irani, Jonathan D. Trobe, WayneCornblath, David I. Kaufman, Eric Eggenberger, Mark J. Kupersmith, William T. Shults; Leslie McAllister, Steve Hamilton, Roy W. Beck, Mariya Dontchev, Robin L. Gal, Craig Kollman, John L. Keltner, Craig H. Smith. Optic neuritis study group multiple sclerosisrisk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727–32.
- Balcer LJ. Optic neuritis. N Engl J Med. 2006;354:1273–80. doi:https://doi.org/10.1056/NEJMcp053247.
- Jin YP, de Pedro-Cuesta J, Soderstrom M, Link H. Incidence of optic neuritis in Stockholm, Sweden, 1990–1995: II. Time and space patterns. Arch Neurol. 1999;56:975–80. doi:https://doi.org/10.1001/archneur.56.8.975.
- Zabad RK, Stewart R, Healey KM. Pattern Recognition of the Multiple Sclerosis Syndrome. Brain Sci. 2017 Oct;7(10):138. doi:https://doi.org/10.3390/brainsci7100138.
- Gašparović I, Čizmarević NS, Lovrečić L, Perković O, Lavtar P, Sepčić J, Jazbec SŠ, Kapović M, Peterlin B, Ristić S, et al. MMP-21575G/A polymorphism modifies the onset of optic neuritis as a first presenting symptom in MS? J Neuroimmunol. 2015 Sep;15(286):13–15. doi:https://doi.org/10.1016/j.jneuroim.2015.06.014.
- Liutkevičienė R, Vilkevičiūtė A, Banevičus M, Miežytė R, Kriaučiūnienė L. Association of MMP-2 (⁻1306 C/T) gene polymorphism with predisposition to optic neuritis and optic neuritis together with multiple sclerosis. Medicina (Kaunas). 2018 May 7;54(2):pii: E29. doi: https://doi.org/10.3390/medicina54020029.
- Banevicius M, Vilkeviciute A, Glebauskiene B, Kriauciuniene L, Liutkeviciene R. Association of optic neuritis with CYP4F2 gene single nucleotide polymorphism and IL-17A concentration. J Ophthalmol. 2018 Mar 15;2018:1686297. doi:https://doi.org/10.1155/2018/1686297.
- Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes. 1998 Jul;47(7):1155–57. doi:https://doi.org/10.2337/diabetes.47.7.1155.
- Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes. 2001;50:1505–11. doi:https://doi.org/10.2337/diabetes.50.6.1505.
- Shao Y, Shao X, He J, Cai Y, Zhao J, Chen F, Tao H, Yin Z, Tan X, He Y, et al. The promoter polymorphisms of receptor for advanced glycation end products were associated with the susceptibility and progression of sepsis. Clin Genet. 2017;91:564–75. doi:https://doi.org/10.1111/cge.12800.
- Zeng L, Zhang AQ, Gu W, Zhou J, Zhang LY, Du DY, Zhang M, Wang HY, Yan J, Yang C, et al. Identification of haplotype tag single nucleotide polymorphisms within the receptor for advanced glycation end products gene and their clinical relevance in patients with major trauma. Crit Care. 2012;16:R131. doi:https://doi.org/10.1186/cc11436.
- Cunha C, Giovannini G, Pierini A, Bell AS, Sorci G, Riuzzi F, Donato R, Rodrigues F, Velardi A, Aversa F, et al. Genetically-determined hyperfunction of the S100B/RAGE axis is a risk factor for aspergillosis in stem cell transplant recipients. PLoS One. 2011;6:e27962. doi:https://doi.org/10.1371/journal.pone.0027962.
- Qin J, Goswami R, Dawson S, Dawson G. Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J Neurosci Res. 2008;86:2414–22. doi:https://doi.org/10.1002/jnr.21692.
- Tiszlavicz Z, Gyulai Z, Bencsik K, Szolnoki Z, Kocsis ÁK, Somogyvári F, Vécsei L, Mándi Y, et al. RAGE gene polymorphisms in patients with multiple sclerosis. J Mol Neurosci. 2009 Nov;39(3):360–65. doi:https://doi.org/10.1007/s12031-009-9291-7.
- Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med. 2009;11:e9. doi:https://doi.org/10.1017/S146239940900101X.
- Sternberg Z, Weinstock-Guttman B, Hojnacki D, Zamboni P, Zivadinov R, Chadha K, Lieberman A, Kazim L, Drake A, Rocco P, et al. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler. 2008;14(6):759–63. doi:https://doi.org/10.1177/1352458507088105.
- Swanton, J. K., Fernando, K., Dalton, C. M., Miszkiel, K. A., Thompson, A. J., Plant, G. T., & Miller, D. H. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. Journal of neurology, neurosurgery, and psychiatry. 2006;77(7), 830–833. https://doi.org/https://doi.org/10.1136/jnnp.2005.073247
- Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, Huerga E, Miszkiel KA, Plant GT, Polman C, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007;6(8):677–86. doi:https://doi.org/10.1016/S1474-4422(07)70176-X.
- Banevicius M, Vilkeviciute A, Kriauciuniene L, Liutkeviciene R, Deltuva VP. The association between variants of receptor for advanced glycation end products (RAGE) gene polymorphisms and age-related macular degeneration. Med Sci Monit. 2018 Jan 10;24:190–99. doi:https://doi.org/10.12659/MSM.905311.
- Wetzels S, Wouters K, Schalkwijk CG, Vanmierlo T, Hendriks JJA. Methylglyoxal-derived advanced glycation endproducts in multiple sclerosis. Int J Mol Sci. 2017 Feb;18(2):421. doi:https://doi.org/10.3390/ijms18020421.
- Li K, Zhao B, Dai D, Yao S, Liang W, Yao L, Yang Z. A functional p.82G>S polymorphism in the RAGE gene is associated with multiple sclerosis in the chinese population. Mult Scler. 2011;17:914–21. doi:https://doi.org/10.1177/1352458511403529.
- Rahimi M, Aghabozorg Afjeh SS, Omrani MD, Arsang-Jang S, Ganji M, Noroozi R, Taheri M, Ghafouri-Fard S. Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a. Cell Physiol Biochem. 2018;46(2):561–567. doi:https://doi.org/10.1159/000488622
- Glasnović A, Cvija H, Stojić M, Tudorić-Đeno I, Ivčević S, Romić D, Tičinović N, Vuletić V, Lazibat I, Grčević D.Decreased level of sRAGE in the cerebrospinal fluid of multiple sclerosis patients at clinical onset. Neuroimmunomodulation. 2014;21(5):226–33. doi:https://doi.org/10.1159/000357002.
- Dobrota D, Cierny D, Michalik J, Kurca E, Lehotsky J. sRage plasma level in association with multiple sclerosis risk in Slovak population. SpringerPlus. 2015;4:P10. doi:https://doi.org/10.1186/2193-1801-4-S1-P10.
- Sternberg Z, Chiotti A, Tario J, Chichelli T, Patel N, Chadha K, Yu J, Karmon Y. Reduced expression of membrane-bound (m)RAGE is a biomarker of multiple sclerosis disease progression. Immunobiology. 2016;221:193–98. doi:https://doi.org/10.1016/j.imbio.2015.09.007.
- Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, Wallström E, Lobell A, Brundin L, Lassmann H, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol. 2008;84:1248–55.
- Jazaeri A, Karimi Moghadam A, Vallian Borujeni S.Evaluating the association between Rs1800624 in RAGE gene and multiple sclerosis in Isfahan population. J Shahid Sadoughi Univ Med Sci. 2016;23(10):923–31.